Indian Startup Leans on Cancer-Sniffing Dogs and AI for Early Detection
THE SO WHAT
Pairing cancer-sniffing dogs with AI on a Bengaluru farm is a low-capex, high-ingenuity way to bootstrap diagnostic datasets where lab infrastructure is scarce. For healthtech builders, it’s a reminder to look for hybrid human/animal/AI workflows that exploit existing biological sensors rather than waiting for perfect hardware or hospital integrations.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechTrump Admin Lets Loose the Cyber Pirates
Authorizing private firms to conduct offensive cyber operations blurs the line between corporate security and state power, raising escalation and attribution risk. Any company operating in critical infrastructure or cross-border data flows should revisit incident response, legal exposure, and insurance assumptions under a world where 'private' cyber reprisals are on the table.
Deep & Emerging TechAsian Memory Chipmakers Rise as Sandisk Outlook Lifts Confidence
Memory names rallying on Sandisk’s AI-driven outlook underlines that the AI boom is as much about bits stored as flops delivered. If you’re planning large model or data-heavy workloads, lock in memory and storage strategy—capacity, vendors, and form factors—before pricing fully bakes in this demand.
Deep & Emerging TechCXMT’s Absence Leaves CSI 300 Missing China’s Biggest Stock
Keeping memory giant CXMT out of the CSI 300 until at least 2027 means China’s flagship index is structurally underweight a core piece of its semiconductor stack. Global allocators tracking the benchmark will be mis‑aligned with China’s actual chip exposure, which matters if you’re planning around where capital—and policy attention—will really land.
Deep & Emerging TechApplied Materials reports Q3 revenue up 25% YoY to $9.12B, vs. $8.99B est., net income up 43% to $2.54B, and forecasts Q4 revenue above estimates
Equipment makers printing 25%+ top-line and 43% profit growth on AI demand means the capex wave into advanced nodes is still accelerating, not peaking. If you're betting on cheaper or more available leading-edge capacity in the near term, revisit your timelines and pricing assumptions.